1. Home
  2. GLTO vs MYSZ Comparison

GLTO vs MYSZ Comparison

Compare GLTO & MYSZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GLTO
  • MYSZ
  • Stock Information
  • Founded
  • GLTO 2011
  • MYSZ 1999
  • Country
  • GLTO Denmark
  • MYSZ Israel
  • Employees
  • GLTO N/A
  • MYSZ N/A
  • Industry
  • GLTO Biotechnology: Pharmaceutical Preparations
  • MYSZ Computer Software: Prepackaged Software
  • Sector
  • GLTO Health Care
  • MYSZ Technology
  • Exchange
  • GLTO Nasdaq
  • MYSZ Nasdaq
  • Market Cap
  • GLTO 4.0M
  • MYSZ 4.0M
  • IPO Year
  • GLTO 2020
  • MYSZ N/A
  • Fundamental
  • Price
  • GLTO $3.29
  • MYSZ $1.27
  • Analyst Decision
  • GLTO Buy
  • MYSZ Strong Buy
  • Analyst Count
  • GLTO 1
  • MYSZ 1
  • Target Price
  • GLTO $10.00
  • MYSZ $3.00
  • AVG Volume (30 Days)
  • GLTO 86.6K
  • MYSZ 119.4K
  • Earning Date
  • GLTO 05-08-2025
  • MYSZ 05-15-2025
  • Dividend Yield
  • GLTO N/A
  • MYSZ N/A
  • EPS Growth
  • GLTO N/A
  • MYSZ N/A
  • EPS
  • GLTO N/A
  • MYSZ N/A
  • Revenue
  • GLTO N/A
  • MYSZ $6,752,000.00
  • Revenue This Year
  • GLTO N/A
  • MYSZ $29.71
  • Revenue Next Year
  • GLTO N/A
  • MYSZ N/A
  • P/E Ratio
  • GLTO N/A
  • MYSZ N/A
  • Revenue Growth
  • GLTO N/A
  • MYSZ N/A
  • 52 Week Low
  • GLTO $2.01
  • MYSZ $1.01
  • 52 Week High
  • GLTO $16.07
  • MYSZ $9.40
  • Technical
  • Relative Strength Index (RSI)
  • GLTO 59.33
  • MYSZ 51.60
  • Support Level
  • GLTO $3.05
  • MYSZ $1.18
  • Resistance Level
  • GLTO $3.49
  • MYSZ $1.34
  • Average True Range (ATR)
  • GLTO 0.26
  • MYSZ 0.09
  • MACD
  • GLTO 0.04
  • MYSZ 0.01
  • Stochastic Oscillator
  • GLTO 75.76
  • MYSZ 65.22

About GLTO Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

About MYSZ My Size Inc.

My Size Inc is a USA-based technology company that focuses on the development of an application that assists the consumer to accurately take the measurements of his or her own body to fit clothing without the need to try them on using a smartphone. The purpose of the company's business is to simplify the process of clothing acquisition through the Internet and to significantly reduce the rate of returns of clothing which were acquired through the internet and which are returned to the stores because of ill-fitting. The company generates its revenue through selling products to customers and licensing cloud-enabled software subscriptions, associated software maintenance, and support.

Share on Social Networks: